N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests

Rapidly growing lab empowers oncologists with actionable precision medicine insights

LEXINGTON, Mass.--()--N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.

NeoGenomics provides a series of NeoTYPE cancer profiling tests that cover various subtypes of solid tumors. Each of the tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor. For each type of cancer, NeoGenomics selected the key driver genes that are central to confirming diagnosis, predicting prognosis, determining or monitoring therapy, and exploring clinical trials options. In many cases, these driver genes can also be targeted for therapy.

N-of-One worked closely with NeoGenomics to configure the depth and breadth of the interpretation required, and tailored the delivery of the content so that it can be efficiently included in NeoGenomics’ unique pathology report. N-of-One delivers highly scalable, cost-effective clinical interpretation that is patient specific and can be configured to the needs of each diagnostic lab.

“NeoGenomics selected N-of-One because of their oncology domain expertise and the flexible and efficient approach to tailoring their interpretation to meet our needs,” said Dr. Maher Albitar, NeoGenomics Chief Medical Officer and Director of Research and Development.

“N-of-One is very pleased to team with NeoGenomics,” said Chris Cournoyer, CEO of N-of-One. “We are focused on helping NeoGenomics meet growing demand for their NGS tests by delivering cost-effective, scalable molecular interpretation that is both patient specific and tailored to how they want to present NGS test results.”

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Fresno, CA, Sacramento, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.

About N-of-One

N-of-One, a leader in enabling precision medicine for oncology, leverages its world-class team of experts coupled with a highly proprietary platform that allows us to provide clinical solutions and services , such as molecular interpretation, to clinicians at the point of care. N-of-One’s team of experts has interpreted thousands of samples for oncologists and patients worldwide, through partnerships with leading diagnostic companies, hospital systems, directly to oncologists and through employee access benefit programs. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.

Contacts

Media:
The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

Release Summary

N-of-One announced an agreement with NeoGenomics, Inc. to provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests.

Contacts

Media:
The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com